ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0256

Interplay Between Na/K-ATPase/Src/ROS Signaling and IL-6/Stat3 Pathway in Obesity-Induced Salt-Sensitive Hypertension

Session Information

Category: Hypertension and CVD

  • 1601 Hypertension and CVD: Basic

Authors

  • Cai, Jiahui, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China
  • Zhao, Shasha, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China
  • Sun, Feifei, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China
  • Pan, Qiaoyun, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China
  • Sun, Yunbo, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China
  • Wang, Danshu, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China
  • Wang, Shuo, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China
  • Liu, Weiping, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China
  • Tan, Qiang, Peking University Third Hospital of Qinhuangdao, Qinhuangdao, China
  • Pierre, Sandrine V., Marshall Institute for Interdisciplinary Research, Marshall University, Huntington, West Virginia, United States
  • Yan, Yanling, Key Labs Nanobiotech & Applied Chemistry, Department of Biotechnology & Engineering, College of Environmental & Chemical Engineering, Yanshan University, Qinhuangdao, China

Group or Team Name

  • S&T Program of Hebei and Hebei Provincial Department of Human Resources and Social Security.
Background

We were the first to identify a novel role of Na/K-ATPase as a receptor in reactive oxygen species (ROS) signaling (Yan et al, JBC, 2013) and its involvement in obesity-induced salt-sensitive hypertension (ssHTN) (Yan et al, IJMS, 2019). The mechanisms responsible for ssHTN are incompletely understood and have been extended to inflammation. Interleukin-6 (IL-6), as a key inflammatory cytokine, promotes ssHTN. However, the impact of IL-6 on renal Na handling via Na/K-ATPase signaling-mediated has yet to be reported. This study investigates the interactions between oxidative stress and inflammation regarding ssHTN.

Methods

Two animal models of obesity were utilized to investigate the Na/K-ATPase/Src/ROS Signaling and IL-6/Stat3 Pathway. Diet-induced obese (DIO) C57BL/6J mice were used to examine the effects of Co(III) Protoporphyrin IX chloride (CoPP, an inducer of heme oxygenase, HO-1) on these signaling pathways, renal sodium handling and blood pressure regulation. Additionally, human and pig renal proximal tubular HK-2 and LLC-PK1 cells were employed for mechanistic analysis.

Results

Our findings revealed that IL-6/Stat3 signaling was activated in the renal cortex tissues of DIO C57BL/6J mice and leptin receptor-deficient obese Zucker rats (Figure 1). In DIO mice, CoPP inhibited the Na/K-ATPase signaling-mediated ROS generation, which impaired renal sodium excretion. This supports our previous findings that ROS is necessary for Na/K-ATPase/Src signaling-mediated natriuresis. Notably, CoPP shifted the renal function curve to the left, indicating reduced blood pressure, likely due to the inhibition of the IL-6/Stat3 signaling pathway (Figure 2).

Conclusion

IL-6/Stat3 signaling significantly contributes to obesity-induced ssHTN, with Na/K-ATPase being essential in this process. Targeting Na/K-ATPase/Src/ROS signaling and proinflammatory IL-6/Stat3 pathway could be a promising therapeutic strategy for treating ssHTN.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)